Redeye provides a research update following the Q1 report recently published by Initiator Pharma. While the company is still awaiting a licensing deal with pudafensine before engaging in further clinical activities, Initiator maintains a very low cash burn. As we have previously stated, the company’s full priority ahead is business development efforts as Initiator continues its pursuit of a licensing partner.
LÄS MER
